Risk of second cancers after photon and proton radiotherapy: A review of the data

Health Physics

Volumn 103, Issue 5, 2012, Pages 577-585

  Yock, Torunn I ^a   Caruso, Paul A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cancer; health effects; medical radiation; National Council on Radiation Protection and Measurements

Indexed keywords

ARTICLE; HUMAN; PHOTON; PROTON THERAPY; RADIATION INDUCED NEOPLASM; RISK; SECOND CANCER; TIME;

HUMANS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PHOTONS; PROTON THERAPY; RISK; TIME FACTORS;

EID: 84867162475     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/HP.0b013e3182609ba4     Document Type: Article

References (71)

1. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, LeisenringW, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:946-958; 2009a.
2. Armstrong GT, Liu Q, Yasui Y, Neglia JP, LeisenringW, Robison LL, Mertens AC. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 27:2328-2338; 2009b.
3. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 174:840-850; 2010.
4. Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D, Robison LL. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 29:3056-3064; 2011.
5. Ashmore JP, Gentner NE, Osborne RV. Incomplete data on the Canadian cohort may have affected the results of the study by the International Agency for Research on Cancer on the radiogenic cancer risk among nuclear industry workers in 15 countries. J Radiol Protect 30:121-129; 2010.
6. Aypar U, Morgan WF, Baulch JE. Radiation-induced genomic instability: are epigenetic mechanisms the missing link? Int J Radiat Biol 87:179-191; 2011.
7. Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, Ronckers CM, Friedman DL, Stovall M, Yasui YY, Robison LL, Meadows AT, Kadan-Lottick NS. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24:476-483; 2006.
8. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12: 353-360; 2011.
9. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23:5493-5500; 2005.
10. Bhatia S. What is the risk of second malignant neoplasms after childhood cancer? Nat Clin Pract Oncol 2:182-183; 2005.
11. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci USA 100: 13761-13766; 2003.
12. Broniscer A, Ke W, Fuller CE, Wu J, Gajjar A, Kun LE. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 100:2246-2252; 2004.
13. Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, Howe G, Kaldor J, Muirhead CR, Schubauer-Berigan M, Yoshimura T, Bermann F, Cowper G, Fix J, Hacker C, Heinmiller B, Marshall M, Thierry-Chef I, Utterback D, Ah n YO, Amoros E, Ashmore P, Auvinen A, Bae JM, Bernar J, Biau A, Combalot E, Deboodt P, Diez Sacristan A, Eklof M, Engels H, Engholm G, Gulis G, Habib RR, Holan K, Hyvonen H, Kerekes A, Kurtinaitis J, Malker H, Martuzzi M, Mastauskas A, Monnet A, Moser M, Pearce MS, Richardson DB, Rodriguez-Artalejo F, Rogel A, Tardy H, Telle-Lamberton M, Turai I, Usel M, Veress K. The 15-country ollaborative study of cancer risk among radiation workers in the nuclear industry: estimates of radiation-related cancer risks. Radiat Res 167:396-416; 2007.
14. Chung CS, Yock T, Johnson J, Esty B, Tarbell N. Proton radiation therapy and the incidence of secondary malignancies. Int J Radiat Oncol Biol Phys 69:S178YS179; 2007.
15. Chung KN, Keating N, Yock T, Tarbell NJ. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. Int J Radiat Oncol Biol Phys 72:S8; 2008.
16. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. Bethesda, MD: National Cancer Institute; NIH Publ. No. 05-5302; 2006.
17. DeLaney TF, Kooy HM. Proton and charged particle radiotherapy. Philadelphia: Lippincott Williams and Wilkins; 2008.
18. Diallo I, Haddy N, Adjadj E, Samand A, Quiniou E, Chavaudra J, Alziar I, Perret N, Guerin S, Lefkopoulos D, de Vathaire F. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 74: 876-883; 2009.
19. Doll R, Wakeford R. Risk of childhood cancer from fetal irradiation. Br J Radiol 70:130-139; 1997.
20. Galloway TJ, Indelicato DJ, Amdur RJ, Morris CG, Swanson EL, Marcus RB. Analysis of dose at the site of second tumor formation after radiotherapy to the central nervous system. Int J Radiat Oncol Biol Phys 82:90-94; 2012.
21. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, Jaspers MW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron HN, van Leeuwen FE. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 297:2705-2715; 2007.
22. Guerin S, Hawkins M, Shamsaldin A, Guibout C, Diallo I, Oberlin O, Brugieres L, de Vathaire F. Treatment-adjusted predisposition to second malignant neoplasms after a solid cancer in childhood: a case-control study. J Clin Oncol 25: 2833-2839; 2007.
23. Hall EJ. Radiobiology for the radiologist. Philadelphia: Lippincott Williams and Wilkins; 2000.
24. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65: 1-7; 2006.
25. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 81:362-378; 2008.
26. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, MathieuMC, Marsiglia H, Bourgier C. Radio-induced malignancies after breast cancer postoperative radiotherapy in patientswith Li-Fraumeni syndrome. RadiatOncol 5:104; 2010.
27. International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. New York: Elsevier; ICRP Publication 60; 1991.
28. International Commission on Radiological Protection. Biological effects after prenatal irradiation (embryo and fetus). Oxford: Pergamon Press; ICRP Publication 90, Ann ICRP 33:1-206; 2003.
29. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens MC. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 91:1905-1910; 2004.
30. Kleinerman RA, Stovall M, Tarone RE, Tucker MA. Gene environment interactions in a cohort of irradiated retinoblastoma patients. Radiat Res 163:701-702; 2005.
31. Kozak KR, Adams J, Krejcarek SJ, Tarbell NJ, Yock TI. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 74:179-186; 2009.
32. Kuttesch JF Jr, Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, Mao L, Delaney TF, Pratt CB, Horowitz ME, Kun LE. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 14:2818-2825; 1996.
33. Little JB. Radiation carcinogenesis. Carcinogenesis 21: 397-404; 2000.
34. Little JB. Genomic instability and bystander effects: a historical perspective. Oncogene 22:6978-6987; 2003.
35. MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, Bortfeld T, Tarbell NJ, Yock T. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71: 979-986; 2008.
36. MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, Tarbell NJ, Yock TI. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys 79:121-129; 2011.
37. Malkin D. Li-fraumeni syndrome. Genes Cancer 2:475-484; 2011.
38. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27:2356-2362; 2009.
39. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 100: 1368-1379; 2008.
40. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54:824-829; 2002.
41. Moteabbed M, Yock T, Paganetti H. Lifetime risk for developing a second malignancy in the high/medium-dose region for pediatric patients for different radiation therapy modalities. Int J Radiat Oncol Biol Phys 81:S796YS797; 2011.
42. NCRP. Second primary cancers and cardiovascular disease after radiotherapy. Bethesda, MD: National Council on Radiation Protection and Measurements; NCRP Report No. 170; 2011.
43. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98: 1528-1537; 2006.
44. NewhauserWD, Fontenot JD, Mahajan A, Kornguth D, Stovall M, ZhengY, Taddei PJ, MirkovicD, Mohan R, Cox JD,Woo S. The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol 54:2277-2291; 2009.
45. Nottage K, Lanctot J, Li Z, Neglia JP, Bhatia S, Hammond S, Leisenring W, Meadows A, Srivastava D, Robison LL, Armstrong GT. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. Blood 117:6315-6318; 2011.
46. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, LeisenringW, Robison LL. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582; 2006.
47. Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H, Kodama K. Studies of the mortality of atomic bomb survivors, Report 14, 1950-2003: an overview of cancer and noncancer diseases. Radiat Res 177: 229-243; 2012.
48. Paganetti H, Bortfeld T, Delaney TF. Neutron dose in proton radiation therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 65:1-7; 2006). Int J Radiat Oncol Biol Phys 66:1594-1595; 2006.
49. Particle Therapy Co-Operative Group. PTCOG: Particle Therapy Co-Operative Group Eonline. 2012. Available at http://ptcog.web.psi.ch/. Accessed 22 March 2012.
50. Pawel D, Preston D, Pierce D, Cologne J. Improved estimates of cancer site-specific risks for A-bomb survivors. Radiat Res 169:87-98; 2008.
51. Pierce DA, Preston DL. Risks from low doses of radiation. Science 272:632b-633b; 1996.
52. Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 154:178-186; 2000.
53. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 160:381-407; 2003.
54. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168:1-64; 2007.
55. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354:34-39; 1999.
56. Ries LAG, Smith MA, Burney JG, Linet M, Tamra T, Bunin GR. Cancer incidence and survival amoung children and adolescents: United States SEER program 1975-1995. Bethesda, MD: National Cancer Institute; 1999.
57. Rombi B, DeLaney TF, MacDonald SM, Huang MS, Ebb DH, Liebsch NJ, Raskin KA, Yeap BY, Marcus KJ, Tarbell NJ, Yock TI. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 82:1142-1148; 2012.
58. Ron E, Modan B, Boice JD Jr, Alfandary E, Stovall M, Chetrit A, Katz L. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 319:1033-1039; 1988.
59. Svahn-Tapper G, Garwicz S, Anderson H, Shamsaldin A, De Vathaire F, Olsen JH, Dollner H, Hertz H, Jonmundsson G, Langmark F, Lanning M, Sankila R, Tulinius H, Moller T. Radiation dose and relapse are predictors for development of second malignant solid tumors after cancer in childhood and adolescence: a population-based case-control study in the five Nordic countries. Acta Oncol 45:438-448; 2006.
60. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, Coray A, Jermann M, Rutz HP, Goitein G. Spotscanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 67:497-504; 2007.
61. Travis LB, Ng AK, Allan JM, Pui C-H, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD Jr. Second cancers and cardiovascular disease following radiotherapy (Commentary). J Natl Cancer Inst 104: 1-14; 2012.
62. Tucker MA, Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, Birch J, Voû te PA, Hoover RN, Fraumeni JF Jr. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78:459-464; 1987a.
63. Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, GreenDM, Lombardi A, NewtonW, Hoover RN, Fraumeni JF Jr. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588-593; 1987b.
64. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81; 1988.
65. U.S. Department of Health and Human Services. Report on carcinogens. Washington, DC: National Toxicology Program 2004.
66. van den Belt-Dusebout AW, deWit R, Gietema JA, Horenblas S, LouwmanMW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378; 2007.
67. Wilson RR. Radiological use of fast protons. Radiology 47(5): 487-491; 1946.
68. Yock TI, Tarbell N. Technology insight: Proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Prac Oncol 1:97-103; 2004.
69. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 63:1161-1168; 2005.
70. Yoon M, Ahn SH, Kim J, Shin DH, Park SY, Lee SB, Shin KH, Cho KH. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 77: 1477-1485; 2010.
71. Zacharatou Jarlskog C, Lee C, Bolch WE, Xu XG, Paganetti H. Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms. Phys Med Biol 53:693-717; 2008.